Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.79 -4.8%	$2.31	$1.11 ▼ $5.00	$476.39M	1.9	1.88 million shs	2.59 million shs
BTMD biote	$3.02	$3.91	$2.76 ▼ $6.98	$149.31M	1.21	173,738 shs	248,494 shs
DAWN Day One Biopharmaceuticals	$6.82 +0.1%	$6.61	$5.64 ▼ $16.76	$698.57M	-1.26	1.39 million shs	1.76 million shs
KALV KalVista Pharmaceuticals	$12.81 -4.0%	$13.44	$7.30 ▼ $16.32	$639.91M	0.05	788,673 shs	595,438 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+5.62%	-23.89%	-21.99%	+22.88%	-49.87%
BTMD biote	+3.42%	+7.09%	-24.88%	-24.12%	-47.84%
DAWN Day One Biopharmaceuticals	+0.89%	+15.42%	+6.41%	+3.50%	-51.08%
KALV KalVista Pharmaceuticals	+3.57%	+6.63%	-13.32%	+8.99%	+11.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	3.0294 of 5 stars	3.5	1.0	0.0	3.8	3.3	0.6
BTMD biote	2.5039 of 5 stars	3.3	2.0	0.0	2.1	1.7	1.3
DAWN Day One Biopharmaceuticals	2.1531 of 5 stars	3.6	2.0	0.0	2.4	1.7	0.0
KALV KalVista Pharmaceuticals	4.0711 of 5 stars	3.6	1.0	4.4	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.12	409.50% Upside
BTMD biote	2.50	Moderate Buy	$6.00	98.68% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$25.29	270.76% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	105.20% Upside

Current Analyst Ratings Breakdown

Latest BTMD, DAWN, AUTL, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$25.00
8/13/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $5.00
8/7/2025	BTMD biote	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$8.00 ➝ $4.00
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$29.93M	15.91	N/A	N/A	$1.61 per share	1.11
BTMD biote	$197.19M	0.76	$0.79 per share	3.81	($2.78) per share	-1.09
DAWN Day One Biopharmaceuticals	$131.16M	5.33	N/A	N/A	$4.99 per share	1.37
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.84	N/A	N/A	N/A	N/A	-56.18%	-29.61%	N/A
BTMD biote	$3.16M	$0.90	3.36	5.59	N/A	15.73%	-21.00%	18.26%	N/A
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	10/29/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)

Latest BTMD, DAWN, AUTL, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
8/12/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.24	-$0.18	+$0.06	-$0.18	$12.92 million	$13.50 million
8/6/2025	Q2 2025	BTMD biote	$0.06	$0.10	+$0.04	$0.10	$49.52 million	$48.86 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
BTMD biote	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	8.43	8.07
BTMD biote	N/A	0.98	0.74
DAWN Day One Biopharmaceuticals	N/A	9.65	9.53
KALV KalVista Pharmaceuticals	N/A	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
BTMD biote	21.68%
DAWN Day One Biopharmaceuticals	87.95%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
BTMD biote	24.00%
DAWN Day One Biopharmaceuticals	6.20%
KALV KalVista Pharmaceuticals	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
BTMD biote	194	49.44 million	37.57 million	Not Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable

BTMD, DAWN, AUTL, and KALV Headlines

Recent News About These Companies

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by Brokerages

August 19 at 2:39 AM | americanbankingnews.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 3.7% - Time to Buy?

August 16 at 12:34 PM | marketbeat.com

Stocks To Watch: KalVista Pharmaceuticals Sees Relative Strength Rating Rise To 82

August 15, 2025 | msn.com

KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50-Day Moving Average - Time to Sell?

August 14, 2025 | marketbeat.com

Stocks With Rising Relative Strength: KalVista Pharmaceuticals

August 12, 2025 | msn.com

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

August 11, 2025 | globenewswire.com

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

August 11, 2025 | finance.yahoo.com

Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria’s navenibart in Japan

August 7, 2025 | fiercebiotech.comF

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2025 | businesswire.com

EMA Backs First Oral Treatment for Hereditary Angioedema

July 29, 2025 | medscape.comM

KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency

July 29, 2025 | msn.com

KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)

July 27, 2025 | seekingalpha.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 6.5% - Here's Why

July 26, 2025 | marketbeat.com

KALV - KalVista Pharmaceuticals Inc Key Metrics - Morningstar

July 25, 2025 | morningstar.comM

New medicines recommended for approval by EMA’s CHMP

July 25, 2025 | thepharmaletter.comT

KalVista Gets CHMP Backing for Ekterly in Hereditary Angioedema

July 25, 2025 | marketwatch.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Crosses Above Fifty Day Moving Average - What's Next?

July 25, 2025 | marketbeat.com

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

July 25, 2025 | businesswire.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

KalVista Pharmaceuticals receives UK MKRA marketing authorization for sebetralstat to treat hereditary angioedema attacks

July 18, 2025 | pharmabiz.comP

MHRA approves KalVista’ Ekterly to treat hereditary angioedema attacks

July 17, 2025 | pmlive.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD, DAWN, AUTL, and KALV Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.79 -0.09 (-4.79%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 -0.01 (-0.50%)

As of 04:58 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

biote NASDAQ:BTMD

$3.02 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.02 0.00 (0.00%)

As of 04:25 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.82 +0.01 (+0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$6.82 +0.00 (+0.07%)

As of 05:27 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

KalVista Pharmaceuticals NASDAQ:KALV

$12.81 -0.53 (-3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$12.80 -0.01 (-0.04%)

As of 04:25 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time